Nagpur News : A Lecture on “ Indian dyslipidemia treatment options” was held recently held recently at Hotel Centre Point, Ramdaspeth, Nagpur by noted Physician & Cardiologist Dr. Shankar Khobragade which was presided over by Dr. Sanjay Jain, Dr. Mukesh Mishra and Dr. R.B. Kalamkar.
Dr. Shankar Khobragade described the Indian scenario of millions of Indian population affected by Diabetes (>55 millions) and how their genetics, eating habits and lifestyle has made us capital of Diabetes. He observed that only less than 18 percent people with type two diabetes achieve ABC goal in USA. They are suppose to have Hb1Ac = <7%, B.P. 130/80mm and Low densisty lipid Cholesterol >100mg./dl. In India 9 out of 10 diabetics have dyslipidemia. In males prevalence is 85% while in females it is 97.8%. Besides, body composition of Asian Indians make them more vulnerable, namely shorter height, lower body mass index, excess body fat in relation to body massindex. Abdominal adioposity High Hip Waste ratio, and high intra-abdominal fat; Trunkal adiposity.
Atherosclerotic Cardiovascular disease (ASCVD) which include, stroke, coronary heart disease,(CHD); peripheral artery disease, all of presumed atherosclerotic origin need to be treated with statins group of drugs to reduce the morbidity and mortality. They are further classified in 4 groups – those with clinical ASCVD, individuals with primary elevations of LDL C < 190mg/dl, individuals with diabetes with LDL-C 70 – 189 mg/dl and individuals without clinical ASCVD or diabertes, who are 40-75 years of age with LDL C < 190mg/dl, and an estimated 10 years ASCVD risk of 7.5% or higher.
A newer molecule “Lipaglyn” invented in India by our scientists have double role as single molecule acting as glucose and lipid lowering agent and is indicated in patients already on statins & anti diabetic drugs who have hyper-triglycerdemia and poor diabetic control .
The lecture was followed by question-answer session in which Dr. S. B. Khobragade dispelled myths answered queries and current concepts.